Pasithea activates two South Korean sites for PAS-004 NF1 trial; first patient dosed

Pasithea Therapeutics Corp.

Two sites activated: Asan Medical Centre and Severance Hospital Yonsei University Health System, both now recruiting.
First patient in South Korea dosed; trial enrolling Cohort 2 (8 mg tablet) after SRC cleared Cohort 1 without modification.
Initial interim clinical data from first two cohorts expected in Q1 2026.
Phase 1/1b study of PAS-004 (macrocyclic MEK inhibitor) in adult NF1 patients with symptomatic plexiform neurofibromas.
Trial also includes sites in Australia and U.S.; Part A dose escalation (4 mg to 18 mg) identifying recommended Part B dose.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.